
		• American Society of Hematology. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia. • Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. • Oncology Nursing Society. Chemotherapy and biotherapy: guidelines and recommendations for practice.


		• Agnogenic Myeloid Metaplasia With Myelofibrosis • Chronic Myelogenous Leukemia • Myelodysplasia • Myeloproliferative Disease • Polycythemia Vera • View All Myeloproliferative Disorders Articles


		• Bone marrow biopsy: Agnogenic myeloid metaplasia • Polycythemia vera. Bone marrow film • Essential thrombocytosis peripheral blood smear • Chronic myelogenous leukemia (CML) in blastic phase • View All Myeloproliferative Disorders Multimedia Files


		• Bone Marrow Biopsy • Leukemia • Lymphoma


		• Platelet disorders. Normal hemostasis.

MYELOPROLIFERATIVE DISORDERS RESOURCE CENTER

Myeloproliferative diseases (MPDs) are a group of disorders characterized by cellular proliferation of one or more hematologic cell lines distinct from acute leukemia. Chronic MPD consist of 4 diseases, including polycythemia rubra vera (PRV), primary thrombocythemia (PT), agnogenic myeloid metaplasia (AMM), and chronic myelogenous leukemia (CML). Another name for AMM is myelofibrosis (MF). In some patients, conditions overlap and clear categorization may be difficult. MPD may evolve into one of the other myeloproliferative conditions and/or transform to acute leukemia.

Myeloproliferative Disease

Hematology

Myelodysplasia

Get 1.5 AMA PRA Category 1 Credit^TM by completing this peer-reviewed online course from eMedicine's Clinical Knowledge Base. Learn the latest point-of-care management of this serious and chronic medical condition that could have long term prognostic implications in this comprehensive review course.

Myelofibrosis

Phase I/II Study of Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

This multicenter trial is evaluating the efficacy of non-myeloablative allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes or myeloproliferative disorders. The incidences of graft-vs-host disease, graft rejection, and non-relapse mortality are also being studied. In addition, the efficacy of a strategy for donor lymphocyte infusion based primarily on defined criteria of persistent or progressive disease in these patients is being evaluated.

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This phase I clinical trial is studying the safety and toxicity of azacitidine in combination with phenylbutyrate in patients with recurrent, refractory, or untreated acute myeloid leukemia or myelodysplastic syndrome. Researchers will also attempt to determine the minimal effective pharmacologic dose of azacitidine required to consistently inhibit DNA methyltransferase in this patient population. Preliminary clinical and/or laboratory data suggesting potential therapeutic activity of this combination regimen in these patients will be obtained.

Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia

This phase II clinical trial is evaluating the effectiveness of bone marrow transplantation, chemotherapy, and biological therapy for chronic myeloid leukemia. The one-year event-free survival in patients with chronic phase chronic myeloid leukemia receiving sargramostim (GM-CSF)-treated autologous bone marrow transplantation, followed by GM-CSF and interferon alfa will be determined. Toxicity of this regimen will also be studied.

Haferlach T, Kern W, Schnittger S, Schoch C. Modern diagnostics in chronic myeloproliferative diseases (CMPDs). Ann Hematol.. 2004;83(suppl 1):S59-61.

Onida F, Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant.. Curr Hematol Rep. 2004 May;3(3):218-26.

Bermejo E, Alberto MF, Meschengieser SS, Lazzari MA. Assessment of platelet activation in myeloproliferative disorders with complementary techniques. Blood Coagul Fibrinolysis. 2004 April;15(3):235-240.

Wong KF. A rapidly progressive chronic myeloproliferative disease with isolated trisomy 6. Cancer Genet Cytogenet. 2004 March;149(2):176-7.

Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res. 2004 June;28(6):657-60.

We subscribe to the
HONcode principles of the
Health On the Net Foundation

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.